Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
756 stopped studies mapped to Acute Leukemia and descendants · 89% state a reason
Over the 756 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03634228 | Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating… | Phase 1 / Phase 2 | terminated | Aug 16, 2018 | M.D. Anderson Cancer Center | This study was terminated early due to lack of adequate response, and did not move to the Phase II… | Other (stated, no rule matched) |
| NCT05645133 | QPlus Pediatric Reference Interval | — | terminated | Dec 9, 2022 | HemoSonics LLC | PI relocated to another institution | Other (stated, no rule matched) |
| NCT05077423 | A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute… | Phase 1 | terminated | Oct 14, 2021 | Y-mAbs Therapeutics | Study terminated due to business priorities | Sponsor / business decision |
| NCT02203773 | Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo)… | Phase 1 | terminated | Jul 30, 2014 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT05256277 | NK Cell Therapy for AML | Phase 1 | terminated | Feb 25, 2022 | Zhejiang University | A new study is planed to replace the current study due to IP upgrade | Other (stated, no rule matched) |
| NCT03705507 | International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of…(SeluDex) | Phase 1 / Phase 2 | terminated | Oct 15, 2018 | University of Birmingham | Poor recruitment, due to a change in the standard of care for this patient population with the use… | Enrollment / accrual |
| NCT03233074 | Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML…(COSMOS) | — | terminated | Jul 28, 2017 | Centre Hospitalier Universitaire de Saint Etienne | Achievement of scientific objectives | Other (stated, no rule matched) |
| NCT03043430 | Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients | Phase 4 | terminated | Feb 6, 2017 | Brooke Army Medical Center | Research manpower shortage | Other (stated, no rule matched) |
| NCT05330377 | GM-CLAG in Relapsed/Refractory FLT3-mutated AML | Phase 1 | withdrawn | Apr 15, 2022 | Ayman H Qasrawi | Sponsor withdrew funding | Funding |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected… | Phase 1 | terminated | Mar 14, 2018 | Amgen | Strategic decisions | Sponsor / business decision |
| NCT05361356 | Spectral CT Clinical Trial | N/A | terminated | May 4, 2022 | Philips (China) Investment CO., LTD | Investigational product had been released in NMPA, Sponsor decided to terminate the study aligned… | Investigator |
| NCT04067180 | Randomized Clinical Study Assessing Haplo vs. URD in AML | N/A | terminated | Aug 26, 2019 | Karolinska Institutet | Delayed enrollment due to COVID-19 pandemic and other non-alterable world events, including war.… | COVID-19 / pandemic |
| NCT04354025 | Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric… | Phase 2 | withdrawn | Apr 21, 2020 | Washington University School of Medicine | Principal investigator decided not to move forward with the study. | Investigator |
| NCT04311866 | Femoral Pediatric Fractures. Walking Spica Cast vs Synthetic Pants | N/A | withdrawn | Mar 17, 2020 | Universidad Autonoma de Nuevo Leon | Lack of material for treatment of the patients | Other (stated, no rule matched) |
| NCT02863458 | DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies… | — | withdrawn | Aug 11, 2016 | The Cleveland Clinic | Study was a data review, no patient recruitment occurred. | Enrollment / accrual |
| NCT03878927 | CPX-351+GO in Subjects 55 Years Old, or Older, With AML(CPX GO) | Phase 1 | terminated | Mar 18, 2019 | Weill Medical College of Cornell University | Dose limiting toxicities. | Safety / toxicity |
| NCT04156659 | Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or… | Phase 2 | withdrawn | Nov 7, 2019 | Novartis Pharmaceuticals | This study was cancelled before enrolling any patients for business related reasons. | Enrollment / accrual |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | Phase 1 | withdrawn | Aug 24, 2022 | Shanghai Pudong Hospital | The study is not initiated and we want it to be withdrawn. | Other (stated, no rule matched) |
| NCT04530695 | Diagnosis and Treatment of Periodontal Disease in Patients With AML | N/A | withdrawn | Aug 28, 2020 | Masonic Cancer Center, University of Minnesota | PI left institution and research was cancelled due to his departure | Investigator |
| NCT04326764 | Panobinostat Maintenance After HSCT fo High-risk AML and MDS | Phase 3 | terminated | Mar 30, 2020 | Goethe University | Change of marketing authorisation holder | Other (stated, no rule matched) |
| NCT00589316 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body… | Phase 1 | terminated | Jan 9, 2008 | Fred Hutchinson Cancer Center | Terminated due to loss of funding | Funding |
| NCT05223699 | Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and… | Phase 1 | terminated | Feb 4, 2022 | Magenta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT02323113 | Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute… | Phase 1 / Phase 2 | terminated | Dec 23, 2014 | Calithera Biosciences, Inc | Business Decision; No Safety or Efficacy Concerns. | Safety / toxicity |
| NCT04095858 | Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease…(CATHY) | Phase 3 | terminated | Sep 19, 2019 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business Reasons | Sponsor / business decision |
| NCT04225676 | Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young… | Phase 2 | terminated | Jan 13, 2020 | Novartis Pharmaceuticals | Terminated due to slow enrollment | Enrollment / accrual |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT05168748 | CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia | Phase 1 | withdrawn | Dec 23, 2021 | Novartis Pharmaceuticals | Sponsor's decision | Sponsor / business decision |
| NCT00119366 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and… | Phase 2 | terminated | Jul 13, 2005 | Fred Hutchinson Cancer Center | Funding ended before target accrual was reached; participants are no longer being examined or… | Enrollment / accrual |
| NCT04343027 | Patient Satisfaction in the Orthopedic Surgery Clinic | N/A | withdrawn | Apr 13, 2020 | NYU Langone Health | Withdrawn project - did not progress to enrollment. | Enrollment / accrual |
| NCT04402723 | Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML | Phase 1 | terminated | May 27, 2020 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Corporate policy adjustments | Other (stated, no rule matched) |
| NCT05571540 | Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | Phase 1 / Phase 2 | withdrawn | Oct 7, 2022 | Kunming Hope of Health Hospital | The PI decides to stop. | Other (stated, no rule matched) |
| NCT04860817 | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and… | Early Phase 1 | withdrawn | Apr 27, 2021 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | No proper participant is found. | Other (stated, no rule matched) |
| NCT03214666 | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | Phase 1 / Phase 2 | terminated | Jul 11, 2017 | GT Biopharma, Inc. | Development of GTB-3550 halted due to development of the second generation camelid nanobody TriKE… | Other (stated, no rule matched) |
| NCT05611086 | N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia | Phase 4 | terminated | Nov 9, 2022 | Teny Tjitra Sari | The study stopped because the study period already ended | Other (stated, no rule matched) |
| NCT03518112 | Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia… | Phase 2 | terminated | May 8, 2018 | M.D. Anderson Cancer Center | Due to Competing Studies | Other (stated, no rule matched) |
| NCT05246384 | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in… | Phase 1 / Phase 2 | withdrawn | Feb 18, 2022 | Rhizen Pharmaceuticals SA | Change in development plan | Other (stated, no rule matched) |
| NCT03410407 | Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)(AML1617) | — | terminated | Jan 25, 2018 | Gruppo Italiano Malattie EMatologiche dell'Adulto | lack of interest | Other (stated, no rule matched) |
| NCT01570465 | Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients(AML1411) | — | terminated | Apr 4, 2012 | Gruppo Italiano Malattie EMatologiche dell'Adulto | low interest | Other (stated, no rule matched) |
| NCT04496999 | HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.(HDMM) | Phase 1 | terminated | Aug 4, 2020 | Insel Gruppe AG, University Hospital Bern | Insufficient recruitment | Enrollment / accrual |
| NCT02618109 | Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute…(LABMI) | Phase 4 | terminated | Dec 1, 2015 | University Hospital, Angers | recruitment difficulties | Enrollment / accrual |
| NCT03516760 | Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia | Phase 1 | terminated | May 4, 2018 | AvenCell Europe GmbH | The actions and measures to be taken to restart the trial could not be implemented which made the… | Other (stated, no rule matched) |
| NCT04282174 | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies(2019-KOE-001) | Phase 2 | withdrawn | Feb 24, 2020 | Baptist Health South Florida | Study was split into two new studies before the first participant was enrolled. | Enrollment / accrual |
| NCT03218683 | Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory… | Phase 1 | terminated | Jul 14, 2017 | AstraZeneca | Sponsor Decision | Sponsor / business decision |
| NCT04425655 | Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed… | Phase 2 | terminated | Jun 11, 2020 | University of California, San Diego | Original investigator for the trial has left | Investigator |
| NCT01440179 | SAR3419 in Acute Lymphoblastic Leukemia(MYRALL) | Phase 2 | terminated | Sep 26, 2011 | Sanofi | The study is stopped due to very modest activity compared to competitors | Other (stated, no rule matched) |
| NCT04272203 | A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose… | Phase 1 | terminated | Feb 17, 2020 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
| NCT02267863 | A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS | Phase 1 | terminated | Oct 20, 2014 | Aptose Biosciences Inc. | Drug manufacturing process and procedure review | Drug supply |
| NCT04006496 | AML Expressive Writing | N/A | terminated | Jul 5, 2019 | Duke University | Recruitment issues due to COVID-19 pandemic. | COVID-19 / pandemic |
| NCT03760666 | A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | terminated | Nov 30, 2018 | Clear Creek Bio, Inc. | No efficacy observed, COVID-19 caused sites to shut down | COVID-19 / pandemic |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 15, 2023source: clinicaltrials